Immupharma (IMM)

 

LSE:IMM: Holding(s) in Company

Immupharma

20 Mar 2017 11:41:45

Immupharma PLC

RNS Number : 9558Z
Immupharma PLC
20 March 2017
 


20 MARCH 2017

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

TR1 NOTIFICATION OF MAJOR INTEREST

 

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has today received a TR-1 by Aviva plc ("Aviva"). Aviva's holding in ImmuPharma is now confirmed at a total of 10,280,516 Ordinary Shares which equates to a current position in the Company of 7.76% of ImmuPharma's total voting rights figure of 132,522,985 Ordinary Shares.

 

 

Full disclosure of the TR1 is shown below:

 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Immupharma plc  

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights


An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):    

 

CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING

 

3. Full name of person(s) subject to the
notification obligation:
iii

Aviva plc & its subsidiaries    

4. Full name of shareholder(s)
 (if different from 3.):iv

Registered Holder:

 

Chase (GA Group) Nominees Limited   : 7,361,243*

 

HSBC Global Custody Nominee (UK) Limited : 1,606,013*

 

State Street Nominees Limited  : 200,974*

 

*denotes direct interest  

 

Chase (GA Group) Nominees Limited  :  409,378

 

Chase Nominees Limited    : 248,294

 

Vidacos Nominees Limited       : 436,614

 

5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

16 March 2017

6. Date on which issuer notified:

17 March 2017

7. Threshold(s) that is/are crossed or
reached:
vi, vii

7% to 6% Change at Direct Interest Level (Box 8A)

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

 

GB0033711010

11,169,942

11,169,942

10,262,516

9,168,230

1,094,286

6.92%

0.83%


 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

RIGHT TO RECALL LOANED SHARES

N/A

N/A

 

18,000*

 

*DIRECT INTEREST

 

0.01%

 

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 










 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

10,280,516

7.76%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

·      Aviva plc (Parent Company)

·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 


Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease
to hold:


12. Date on which proxy holder will cease to hold
voting rights:




13. Additional information:


Figures are based the revised total number of voting rights of 132,522,985 as per the recent £4.1 Million Fund Raise via Accelerated Bookbuild announcement of 10 March 2017.

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

 01603 684420

 

 

 

 

 

 

 

 

-Ends-

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited (NOMAD & Broker)

Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625








 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFBLFLDXFXBBV